WO2013147577A1 - Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné - Google Patents
Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné Download PDFInfo
- Publication number
- WO2013147577A1 WO2013147577A1 PCT/MX2013/000027 MX2013000027W WO2013147577A1 WO 2013147577 A1 WO2013147577 A1 WO 2013147577A1 MX 2013000027 W MX2013000027 W MX 2013000027W WO 2013147577 A1 WO2013147577 A1 WO 2013147577A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- semi
- acne
- topical composition
- composition according
- solid topical
- Prior art date
Links
- 206010000496 acne Diseases 0.000 title claims abstract description 84
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 79
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 230000000699 topical effect Effects 0.000 title claims abstract description 49
- 239000007787 solid Substances 0.000 title claims abstract description 43
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 title claims abstract description 34
- 229960003073 pirfenidone Drugs 0.000 title claims abstract description 32
- PFRGXCVKLLPLIP-UHFFFAOYSA-N diallyl disulfide Chemical class C=CCSSCC=C PFRGXCVKLLPLIP-UHFFFAOYSA-N 0.000 title claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 21
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 16
- 238000011282 treatment Methods 0.000 claims abstract description 15
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 12
- 239000004599 antimicrobial Substances 0.000 claims abstract description 10
- 230000002441 reversible effect Effects 0.000 claims abstract description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 18
- 239000003349 gelling agent Substances 0.000 claims description 11
- 229920002125 Sokalan® Polymers 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 6
- 208000032544 Cicatrix Diseases 0.000 claims description 6
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 claims description 6
- 229960001631 carbomer Drugs 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 229940072106 hydroxystearate Drugs 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 231100000241 scar Toxicity 0.000 claims description 6
- 230000037387 scars Effects 0.000 claims description 6
- -1 Diallyl Modified Disulfide Chemical class 0.000 claims description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 5
- 208000037976 chronic inflammation Diseases 0.000 claims description 5
- 230000006020 chronic inflammation Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 229920000058 polyacrylate Polymers 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 238000013019 agitation Methods 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 230000003902 lesion Effects 0.000 abstract description 15
- 230000002421 anti-septic effect Effects 0.000 abstract description 6
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 4
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 230000003510 anti-fibrotic effect Effects 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000002757 inflammatory effect Effects 0.000 description 21
- 241000186427 Cutibacterium acnes Species 0.000 description 18
- 244000005700 microbiome Species 0.000 description 15
- 210000001732 sebaceous gland Anatomy 0.000 description 14
- 210000002374 sebum Anatomy 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 13
- 230000004054 inflammatory process Effects 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 230000000770 proinflammatory effect Effects 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 229940055019 propionibacterium acne Drugs 0.000 description 8
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 239000003098 androgen Substances 0.000 description 7
- 229940030486 androgens Drugs 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000000589 Interleukin-1 Human genes 0.000 description 5
- 108010002352 Interleukin-1 Proteins 0.000 description 5
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 5
- 102100023118 Transcription factor JunD Human genes 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000003325 follicular Effects 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000003780 keratinization Effects 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 3
- 101800000414 Corticotropin Proteins 0.000 description 3
- 241000555688 Malassezia furfur Species 0.000 description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229960000258 corticotropin Drugs 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229940031439 squalene Drugs 0.000 description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003760 tallow Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 description 2
- 240000002234 Allium sativum Species 0.000 description 2
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000014429 Insulin-like growth factor Human genes 0.000 description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- MNLRQHMNZILYPY-MDMHTWEWSA-N N-acetyl-alpha-D-muramic acid Chemical compound OC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@@H]1NC(C)=O MNLRQHMNZILYPY-MDMHTWEWSA-N 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- 102000034527 Retinoid X Receptors Human genes 0.000 description 2
- 108010038912 Retinoid X Receptors Proteins 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000037386 abnormal desquamation Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 description 2
- 235000010081 allicin Nutrition 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000002019 disulfides Chemical class 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 235000004611 garlic Nutrition 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000003488 releasing hormone Substances 0.000 description 2
- 230000003938 response to stress Effects 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- QZDDFQLIQRYMBV-UHFFFAOYSA-N 2-[3-nitro-2-(2-nitrophenyl)-4-oxochromen-8-yl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2[N+]([O-])=O)=O)=C1OC=2C1=CC=CC=C1[N+]([O-])=O QZDDFQLIQRYMBV-UHFFFAOYSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108010049990 CD13 Antigens Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 1
- 102000015689 E-Selectin Human genes 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 240000004928 Paspalum scrobiculatum Species 0.000 description 1
- 206010035502 Plasmodium ovale infection Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 239000004164 Wax ester Substances 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 231100001039 immunological change Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006680 metabolic alteration Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004148 metal metabolism Effects 0.000 description 1
- XMYQHJDBLRZMLW-UHFFFAOYSA-N methanolamine Chemical compound NCO XMYQHJDBLRZMLW-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000007269 microbial metabolism Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000012009 microbiological test Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- IOQPZZOEVPZRBK-UHFFFAOYSA-O octylazanium Chemical compound CCCCCCCC[NH3+] IOQPZZOEVPZRBK-UHFFFAOYSA-O 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- NNNVXFKZMRGJPM-KHPPLWFESA-N sapienic acid Chemical compound CCCCCCCCC\C=C/CCCCC(O)=O NNNVXFKZMRGJPM-KHPPLWFESA-N 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000004378 sebocyte Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000019386 wax ester Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention relates to a semi-solid topical composition containing 8% Pirfenidone and 0.016% Modified Dialyl Oxide (ODD-M) that act synergistically to eliminate or prevent the occurrence of various forms of acne on the skin and as antimicrobial and antiseptic.
- ODD-M Modified Dialyl Oxide
- Acne is an inflammatory disease of the pilosebaceous follicles, associated with alterations of keratinization and seborrhea; It is characterized by the formation of skin lesions such as comedones, papules, pustules, cysts or abscesses, which often leave residual scars.
- PPAR nuclear receptors act in concert with retinoid X receptors (RXR), to regulate the growth and differentiation of the epidermis, as well as lipid metabolism Transcriptional factors of sterols regulate the increase in sebaceous lipid formation induced by insulin-like growth factor (IGF-1).
- RXR retinoid X receptors
- IGF-1 insulin-like growth factor
- Other research on the function of the sebaceous gland has contributed to obtaining information about the main role that these glands play in the regulation of skin functions.
- the sebaceous gland has direct and indirect antibacterial activities. (Sapienic acid, a lipid in tallow) has innate antimicrobial activity and is increased by activation of the Toll 2 receptor (TLR-2) by contact with bacteria on the skin.
- TLR-2 Toll 2 receptor
- the sebaceous gland produces antibacterial peptides and proinflammatory cytokines, which are induced in sebum cells due to the presence of bacteria.
- the sebaceous gland acts as an endocrine organ that responds to changes in androgens and hormones and is the control center for a complex program that regulates neuropeptides that act as the hypothalamic-pituitary-adrenal axis.
- This function of the sebaceous gland is mainly influenced by the corticotrophin releasing hormone, the protein that binds to it, and by corticotrophin receptors.
- Corticotrophin-releasing hormone levels change in response to stress and its role as a regulator of the function of the sebaceous gland is to act as a brain-skin connection that explains the relationship between stress and inflammatory skin disorders, especially dermatitis Atopic and acne. Additionally, it has been reported that receptors for ectopeptidases such as Dipeptidylpeptidase IV and aminopeptidase-N have a preponderant role in the regulation of sebocytes.
- acnes on the other hand, seems to play a central role in the development of inflammation in acne. Perhaps the most striking evidence is the demonstration that antibiotic therapy results in a significant suppression of P. acnes, which is accompanied by a reduction in the number of inflammatory lesions.
- Propionibacterium acnes and Staphylococcus epidermidis are producers of a lipase that hydrolyzes tallow triglycerides into free fatty acids, which are potent irritants of the follicular canal, when applied to the skin or injected intradermally, cause inflammation and comedones. It should also be noted that the Propionibacterium acnes, activates the complement system alternately, which has allowed it to be postulated that this infectious mechanism could also play an important role in the production of inflammatory acne lesions.
- MMP's matrix metalloproteinases
- TLR-2 TOLL-LIKE-2 receptor that triggers these inflammatory responses.
- This transmembrane protein has a cytoplasmic portion, which is homologous to the receptor for Interleukin 1 (IL-1), therefore, in this way the signaling cascade that activates the nuclear transcriptional factor Kappa-B (NF-kp) can be triggered.
- IL-1 Interleukin 1
- AP-1 Activator Protein-1
- MMP genes' s whose products degrade and alter the matrix of the dermis.
- Propionibacterium acnes also induces Toll-like receptors. This provides additional evidence that inflammatory cytokines, which act through autocratic and paracrine mechanisms amplify their corresponding receptors and amplify the signaling pathway that activates Activator Protein-1 (AP-1) which is a transcriptional factor.
- Pirfenidone and ODD-M The combination of two elements whose ultimate goal is the symptomatic management of acne and its sequelae, Pirfenidone and ODD-M, has been shown to have important effects treating patients with acne with different stages and severity of lesions, from mild to severe, showing an improvement in the severity, number of injuries and the duration of them, primary objectives for the doctor who treats acne.
- acne has a complex interaction of many factors that intersect to create a complex problem where some key points are finally confluent in genetic factors and inflammation such as:
- P. acnes contributes to inflammation via activation of Toll-like receptors in the membranes of inflammatory cells.
- Sebum production is partially regulated by PPAR receptors.
- the sebaceous gland is a neuroendrocrine-inflammatory organ that coordinates and executes a local response to stress and normal functions.
- Oxidized lipids in sebum can stimulate the production of inflammatory mediators.
- MMP's Matrix metalloproteases
- the main objective of the present invention is to provide semi-solid topical compositions to eliminate, reduce or prevent the occurrence of acne in the skin that preferably comprise 8% by weight of the composition of pirfenidone [1- phenyl-5-methyl-2- ( 1 H) -pyridone] and ODD-M at a concentration of 0.016%, a gelling agent and one or more excipients or additives.
- Another object of the invention is the use of ODD-M as an antimicrobial and antiseptic agent eliminating the need for the use of other preservative agents in the composition.
- another object of the invention is the method of treatment and / or pharmaceutical application or use of a semi-solid topical composition containing pirfenidone and ODD-M to eliminate, reduce or prevent acne.
- said semi-solid topical composition acts to prevent chronic inflammation caused by acne, to decrease the reddish tone of the skin, to stop the formation of new acne breakouts, to reverse existing outbreaks, to regenerate damaged skin accordingly. of acne and to avoid and disappear post-technical scars.
- Figure 2 demonstrates the molecular chain for the production of dermal sequelae.
- Figure 3 schematizes the system of transmission of signals at the cellular level that intervene in acne and that ultimately trigger the inflammatory process.
- Figures 4-15 clearly show the therapeutic effects of the semi-solid topical composition of pirfenidone containing ODD-M to eliminate or prevent acne in twelve patients with different types of acne.
- the present invention relates to a semi-solid topical composition in the form of a gel, cream or ointment comprising [1-phenyl-5-methyl-2- (1 H) -pyridone] preferably 8%, an agent gelling agent, cellulose derivatives, polyacrylic crosslinked acid polymers and carboxyvinyl derivatives; and other additives such as triethanolamine as neutralizing agent, propylene glycol as solubilizer, macrogol-glycerol hydroxystearate as a non-ionic solubilizer, among others commonly used in the production of gels.
- the semi-solid topical composition contains 0.016% weight / volume of an antimicrobial and antiseptic such as ODD-M.
- [1-Phenyl-5-methyl-2- (1 H) -pyridone] is a drug that has been applied in the restoration of tissues with fibrotic lesions and for the prevention of fibrotic lesions.
- This compound, called Pirfenidone is itself a known compound and its pharmacological effects have been described in, for example, Japanese applications KOKAI Nos. 87677/1974 and 1284338/1976, as an anti-inflammatory agent that includes anti-inflammatory effects.
- -Pyretic and analgesic U.S. Patents Nos.
- Pirfenidone and ODD-M generates a semi-solid topical composition that prevents, stops and eliminates in a short time the skin problems due to acne. It acts as an anti-inflammatory and antimicrobial agent due to its dual mechanism of action, since in addition to blocking the pro-inflammatory cytokines - especially TNF- ⁇ (Tumor Necrosis Factor-alpha), it also has antimicrobial and antiseptic action. This acts on two of the main causes of acne.
- the semi-solid topical composition of Pirfenidone and ODD-M ⁇ Has a direct effect blocking TNF ⁇ , TGF ⁇ and other pro-inflammatory cytokines.
- the semi-solid topical composition allows the pharmacological properties of pirfenidone and ODD-M to act synergistically on the skin, so the selection of gelling agents is of paramount importance. Consequently the gelling agents were selected from the group that It consists of: methylcellulose, hydroxypropylcellulose, sodium carboxymethylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl, carbomer, acrylic polymers. These gelling agents are used together with additives that allow the pH to be reached from 5 to 6.4, at which these gelling agents obtain their highest viscosity. Said composition also comprises ODD-M, propylene glycol, macrogol-glycerol hydroxystearate and triethanolamine.
- semi-solid topical compositions for reducing or preventing the occurrence of acne on the skin comprising preferably 8% by weight of the pirfenidone composition and 85 to 95% by weight of the composition of a gelling agent are object of the present invention.
- a gelling agent selected from the group consisting of methyl cellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose, polyvinyl alcohol, polyvinyl pyrrolidone, carboxyvinyl polymers, carbomer, acrylic polymers; and one or more other additives selected from propylene glycol, macrogol-glycerol hydroxystearate, in addition to ODD-M.
- the semi-solid topical composition is effective to prevent chronic inflammation caused by acne, to decrease the reddish tone of the skin, to stop the formation of new acne breakouts, to reverse existing outbreaks, to regenerate damaged skin to consequence of acne and to avoid and disappear post-technical scars.
- the semi-solid topical composition containing Pirfenidone and ODD-M is manufactured according to a process comprising the following steps:
- step 4 Add the container (step 1) one by one, with constant stirring until homogenized each time and in the order indicated.
- composition of Pirfenidone and ODD-M at 0.016% described in this invention allows to obtain a gel, cream or ointment containing a stable, biodegradable, nontoxic contact antimicrobial / antiseptic and with a wide spectrum of action, not only against large negative microorganisms and Great positives, but also against fungi.
- Figure 1 shows the chemical formula of the Modified Diallyl Disulfide Oxide [ODD-M], whose chemical name is [1,2-diallyl-1- (5-methyl-tetrahydro-2H-pyran-2- iloxy) disulfuronium] + 6 - [(benzyl, methyl, octylammonium) (hydroxymethylamine) (methylamine)] - tetrahyde-2H-pyran-3-oxy] chloride:
- Tables 1, 2, 3 and 4 compile the information obtained after performing the microbiological tests or also called the ODD-M antimicrobial challenge against various bacteria, demonstrating its great antibacterial capacity.
- Table 5 shows the results of ODD-M against Propionibacterium acnes.
- this table also demonstrates that the combination of Pirfenidone and ODD-M (semi-solid topical composition containing Pirfenidone and ODD-M) results in the highly effective removal in seconds of P. acnes.
- ROS reactive oxygen species
- the number of injuries of each patient was counted according to the degree to which the subject belonged.
- the resulting data are presented in Table 8, where it can be seen that the treatment resulted in a reduction, on average, close to 50% in inflammatory lesions after 28 days of treatment.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/388,447 US20150148382A1 (en) | 2012-03-28 | 2013-02-27 | Semi-solid topical composition which contains pirfenidone and modified diallyl disulphide oxide (m-ddo) for eliminating or preventing acne |
CA2868729A CA2868729C (en) | 2012-03-28 | 2013-02-27 | Semi-solid topical composition containing pirfenidone and modified diallyl disulfide oxide (m-ddo) for eliminating or preventing acne |
KR1020147030122A KR20140146144A (ko) | 2012-03-28 | 2013-02-27 | 여드름을 제거 또는 예방하기 위한 피르페니돈과 변성 다이알릴 다이설파이드 옥사이드(m-ddo)를 함유하는 반고체 국소 조성물 |
IN8067DEN2014 IN2014DN08067A (es) | 2012-03-28 | 2013-02-27 | |
JP2015503144A JP2015513359A (ja) | 2012-03-28 | 2013-02-27 | 座瘡の排除又は予防用のピルフェニドンと改変ジアリルジスルフィド酸化物(m−ddo)とを含む半固形局所組成物 |
MA37377A MA20150062A1 (fr) | 2012-03-28 | 2013-02-27 | Composition topique semi-solide contenant de la pirfénidone et de l'oxyde de disulfure dialyle modifié (odd-m) pour éliminer ou prévenir l'acné |
EA201401031A EA201401031A1 (ru) | 2012-03-28 | 2013-02-27 | Полутвёрдая композиция для местного применения, которая содержит пирфенидон и модифицированный диаллилдисульфид оксид (m-ddo) для удаления или предупреждения угрей |
AU2013240709A AU2013240709A1 (en) | 2012-03-28 | 2013-02-27 | Semi-solid topical composition which contains pirfenidone and modified diallyl disulphide oxide (m-ddo) for eliminating or preventing acne |
SG11201406035VA SG11201406035VA (en) | 2012-03-28 | 2013-02-27 | Semi-solid topical composition which contains pirfenidone and modified diallyl disulphide oxide (m-ddo) for eliminating or preventing acne |
EP13716457.0A EP2832354A1 (en) | 2012-03-28 | 2013-02-27 | Semi-solid topical composition which contains pirfenidone and modified diallyl disulphide oxide (m-ddo) for eliminating or preventing acne |
CN201380023489.8A CN104334171A (zh) | 2012-03-28 | 2013-02-27 | 用于消除或预防痤疮的包含吡非尼酮和改性二烯丙基二硫化物氧化物(m-ddo)的半固体局部组合物 |
TNP2014000396A TN2014000396A1 (en) | 2012-03-28 | 2014-09-22 | Semi-solid topical composition which contains pirfenidone and modified diallyl disulphide oxide (m-ddo) for eliminating or preventing acne |
IL234816A IL234816A0 (en) | 2012-03-28 | 2014-09-23 | A semi-solid topical preparation containing pirfenidone and modified diallyl disulfide oxide for the treatment or prevention of acne |
PH12014502154A PH12014502154A1 (en) | 2012-03-28 | 2014-09-26 | Semi-solid topical composition which contains pirfenidone and modified diallyl disulphide oxide (m-ddo) for eliminating or preventing acne |
CU2014000114A CU20140114A7 (es) | 2012-03-28 | 2014-09-26 | Compisición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné |
US15/098,970 US9949959B2 (en) | 2012-03-28 | 2016-04-14 | Semi-solid topical composition containing pirfenidone and modified diallyl disulfide oxide (M-DDO) for eliminating or preventing acne |
US15/920,822 US20180214434A1 (en) | 2012-03-28 | 2018-03-14 | Semi-solid topical composition containing pirfenidone and modified diallyl disulfide oxide (m-ddo) for eliminating or preventing acne |
US16/534,980 US11013727B2 (en) | 2012-03-28 | 2019-08-07 | Semi-solid topical composition containing pirfenidone and modified diallyl disulfide oxide (M-DDO) for eliminating or preventing acne |
US17/328,685 US11766426B2 (en) | 2012-03-28 | 2021-05-24 | Semi-solid topical composition containing pirfenidone and modified diallyl disulfide oxide (M-DDO) for eliminating or preventing acne |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXMXA/2012/003694 | 2012-03-28 | ||
MX2012003694A MX346763B (es) | 2012-03-28 | 2012-03-28 | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/388,447 A-371-Of-International US20150148382A1 (en) | 2012-03-28 | 2013-02-27 | Semi-solid topical composition which contains pirfenidone and modified diallyl disulphide oxide (m-ddo) for eliminating or preventing acne |
US15/098,970 Continuation US9949959B2 (en) | 2012-03-28 | 2016-04-14 | Semi-solid topical composition containing pirfenidone and modified diallyl disulfide oxide (M-DDO) for eliminating or preventing acne |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013147577A1 true WO2013147577A1 (es) | 2013-10-03 |
Family
ID=48096131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/MX2013/000027 WO2013147577A1 (es) | 2012-03-28 | 2013-02-27 | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné |
Country Status (22)
Country | Link |
---|---|
US (5) | US20150148382A1 (es) |
EP (1) | EP2832354A1 (es) |
JP (1) | JP2015513359A (es) |
KR (1) | KR20140146144A (es) |
CN (1) | CN104334171A (es) |
AR (1) | AR090457A1 (es) |
AU (1) | AU2013240709A1 (es) |
CA (1) | CA2868729C (es) |
CL (1) | CL2014002591A1 (es) |
CO (1) | CO7071140A2 (es) |
CU (1) | CU20140114A7 (es) |
DO (1) | DOP2014000218A (es) |
EA (1) | EA201401031A1 (es) |
IL (1) | IL234816A0 (es) |
IN (1) | IN2014DN08067A (es) |
MA (1) | MA20150062A1 (es) |
MX (1) | MX346763B (es) |
PH (1) | PH12014502154A1 (es) |
SG (1) | SG11201406035VA (es) |
TN (1) | TN2014000396A1 (es) |
UY (1) | UY34700A (es) |
WO (1) | WO2013147577A1 (es) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9949959B2 (en) | 2012-03-28 | 2018-04-24 | Cell Therapy and Technology S.A. DE C.V. | Semi-solid topical composition containing pirfenidone and modified diallyl disulfide oxide (M-DDO) for eliminating or preventing acne |
US10233195B2 (en) | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10376500B2 (en) | 2007-08-14 | 2019-08-13 | Cell Therapy and Technology S.A. DE C.V. | Gel containing pirfenidone |
WO2020046102A3 (es) * | 2018-08-31 | 2020-09-10 | Cell Therapy and Technology S.A. DE C.V. | Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular |
US10792258B2 (en) | 2012-08-23 | 2020-10-06 | Excalibur Pharmaceuticals, Inc. | Antiseptic, antiseborrheic and exfoliating composition to remove or prevent acne |
US11040030B2 (en) | 2011-07-19 | 2021-06-22 | Excalibur Pharmaceuticals, Inc. | Methods of using a pharmaceutical composition containing pirfenidone in sustained-release tablet form |
US11576905B2 (en) | 2017-08-15 | 2023-02-14 | Excalibur Pharmaceuticals, Inc. | Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106491517B (zh) * | 2016-11-23 | 2019-12-06 | 佛山科学技术学院 | 吡非尼酮pva水凝胶的制备方法及吡非尼酮pva水凝胶 |
US20180360751A1 (en) * | 2017-06-19 | 2018-12-20 | Advanced Fibrosis Research LLC | Transdermal cream for treating Dupuytren's Contracture |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4987677A (es) | 1972-12-18 | 1974-08-22 | ||
US3839346A (en) | 1972-12-18 | 1974-10-01 | Affiliated Med Res | N-substituted pyridone and general method for preparing pyridones |
US3974281A (en) | 1972-12-18 | 1976-08-10 | Affiliated Medical Research, Inc. | 5-Methyl-1-phenyl-2-(1H)-pyridone compositions and methods of use |
JPS51128433A (en) | 1975-04-30 | 1976-11-09 | Ajinomoto Co Inc | A herbicide |
US4042699A (en) | 1972-12-18 | 1977-08-16 | Affiliated Medical Research, Inc. | Method for reducing serum glucose levels |
US4052509A (en) | 1972-12-18 | 1977-10-04 | Affiliated Medical Research, Inc. | Method for reducing serum uric acid levels |
EP2177220A1 (en) * | 2007-08-14 | 2010-04-21 | Cell Therapy Technology, S.A. DE C.V. | Gel containing pirfenidone |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4105782A (en) | 1975-03-07 | 1978-08-08 | Yu Ruey J | Treatment of acne and dandruff |
SE430609B (sv) | 1976-12-21 | 1983-11-28 | Sca Development Ab | Sett att ur cellulosaderivat framstella absorberande material |
US4376118A (en) | 1980-10-06 | 1983-03-08 | Miles Laboratories, Inc. | Stable nonaqueous solution of tetracycline salt |
US5310562A (en) | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
US5009895A (en) | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
CA2161648A1 (en) | 1993-05-07 | 1994-11-24 | Solomon B. Margolin | Compositions and methods for reparation and prevention of fibrotic lesions |
CA2239352C (en) | 1995-12-21 | 2002-06-04 | Pfizer Inc. | Injectable quinolone formulations |
US5958420A (en) | 1997-03-13 | 1999-09-28 | Nortrade Medical, Inc. | Treatment of burns, cuts, and abrasions of the skin |
US6365131B1 (en) | 1997-10-31 | 2002-04-02 | J. B. Chemicals & Pharmaceuticals Ltd. | Pharmaceutical dental formulation for topical application of metronidazole benzoate, chlorhexidine gluconate and local anesthetic |
WO1999047140A1 (en) | 1998-03-17 | 1999-09-23 | Margolin Solomon B | Topical antiseptic compositions and methods |
GB9810949D0 (en) | 1998-05-22 | 1998-07-22 | Hewlett Healthcare Limited | Formulation |
DE69810518D1 (de) | 1998-09-18 | 2003-02-06 | Mepha Ag Aesch | Topisch verabreichbare alkyl-, phenyl-pyridone-arzneimittel |
US20020028784A1 (en) | 2000-03-10 | 2002-03-07 | Nest Gary Van | Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences |
IN191090B (es) | 2000-08-29 | 2003-09-20 | Ranbanx Lab Ltd | |
DE60234812D1 (de) | 2001-01-29 | 2010-02-04 | Shionogi & Co | Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält |
AU2002348534A1 (en) | 2001-10-09 | 2003-04-22 | The Children's Hospital Of Philadelphia | Materials and methods for preventing or reducing scar formation |
CH696420A5 (de) | 2002-09-13 | 2007-06-15 | Mepha Ag | Neue stabile Zubereitungen von Alkyl-, Phenyl-Pyridonen für topische Anwendung. |
TW200501952A (en) | 2003-02-21 | 2005-01-16 | Shionogi & Co | Pirfenidone gel formulations |
AU2003299962A1 (en) | 2003-02-28 | 2004-09-28 | Intermune, Inc. | Interferon drug therapy for the treatment of viral diseases and liver fibrosis |
AU2003225670A1 (en) | 2003-02-28 | 2004-09-28 | Intermune, Inc. | Interferon drug therapy for the treatment of viral diseases and liver fibrosis |
WO2004089283A2 (en) | 2003-04-04 | 2004-10-21 | Intermune, Inc. | Compositions and methods for treating viral infections |
WO2005062739A2 (en) * | 2003-05-23 | 2005-07-14 | Ott David M | S-allylmercaptocysteine prodrugs and methods of treatment |
US20080025986A1 (en) | 2003-06-06 | 2008-01-31 | Ozes Osman N | Methods of Treating Tnf-Mediated Disorders |
EP2407470A3 (en) | 2003-10-14 | 2015-06-10 | F. Hoffmann-La Roche Ltd. | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication |
US7491794B2 (en) | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
US7407973B2 (en) | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
US20070258946A1 (en) | 2003-12-23 | 2007-11-08 | Blatt Lawrence M | Combination Therapy for Treating Hepatitis C Virus Infection |
CN100542532C (zh) | 2004-05-24 | 2009-09-23 | 上海睿星基因技术有限公司 | 吡非尼酮在制备治疗肝损伤坏死和急性肺损伤的药物中的用途 |
US20060051339A1 (en) | 2004-09-08 | 2006-03-09 | Sivak Hannah N | Composition for treatment of oily skin and acne prevention and methods of making and using same |
US20060115503A1 (en) | 2004-11-30 | 2006-06-01 | Goyal Muna C | Composition, system and method for treatment of skin |
AU2006244072B2 (en) | 2005-05-10 | 2012-09-20 | Intermune, Inc. | Pyridone derivatives for modulating stress-activated protein kinase system |
BRPI0613962A2 (pt) | 2005-07-25 | 2009-03-24 | Intermune Inc | inibidores macrocìclicos inovadores de replicação de vìrus da hepatite c |
NZ591443A (en) | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
EP1960405A2 (en) | 2005-11-23 | 2008-08-27 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
US8586078B2 (en) | 2005-12-05 | 2013-11-19 | Rba Pharma Inc. | Emulsion-containing medical articles |
CN101088557A (zh) | 2006-06-12 | 2007-12-19 | 天津市扶素生物技术有限公司 | 用于预防或治疗hiv感染的药用组合物及其应用 |
WO2008100867A2 (en) | 2007-02-12 | 2008-08-21 | Intermune, Inc. | Novel inhibitors hepatitis c virus replication |
JP2010520194A (ja) | 2007-03-02 | 2010-06-10 | ミロン、タリア | 抗癌剤としてのメルカプトプリン誘導体 |
US20080287508A1 (en) | 2007-05-18 | 2008-11-20 | Intermune, Inc. | Altering pharmacokinetics of pirfenidone therapy |
CN104892498A (zh) | 2007-06-20 | 2015-09-09 | 奥斯拜客斯制药有限公司 | 作为纤维化抑制剂的取代的n-芳基吡啶酮 |
US20090137354A1 (en) | 2007-11-27 | 2009-05-28 | Shimano Inc. | Bicycle rear derailleur |
US20110300130A1 (en) | 2007-12-11 | 2011-12-08 | Becker David L | Impaired wound healing compositions and treatments |
US20100256031A1 (en) | 2008-10-10 | 2010-10-07 | Jeffrey Wu | Shine control cleanser |
US7635707B1 (en) | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
CN101972225A (zh) | 2010-10-13 | 2011-02-16 | 北京诚创康韵医药科技有限公司 | 一种含吡非尼酮的凝胶组合物 |
CN101972236A (zh) | 2010-10-13 | 2011-02-16 | 北京诚创康韵医药科技有限公司 | 一种含吡非尼酮的缓释制剂 |
CA2824432C (en) | 2011-01-31 | 2021-10-19 | Genoa Pharmaceuticals, Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
EP3578178A1 (en) | 2011-02-15 | 2019-12-11 | Aclaris Therapeutics, Inc. | Pharmaceutical composition comprising oxymetazoline |
CN102670600A (zh) | 2011-03-12 | 2012-09-19 | 赵海静 | 一种抑制瘢痕和促进创口愈合的医药产品,其制备方法和应用 |
CN102670632A (zh) | 2011-03-12 | 2012-09-19 | 赵海静 | 吡非尼酮在抑制皮肤瘢痕形成的医药用途 |
US9241921B2 (en) | 2011-05-02 | 2016-01-26 | Pankaj Modi | Photosensitizer composition for treating skin disorders |
MX2011007675A (es) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
CN102488660A (zh) | 2011-12-15 | 2012-06-13 | 西安天一秦昆制药有限责任公司 | 一种含吡非尼酮的缓释微丸 |
MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
WO2013181691A1 (en) | 2012-06-04 | 2013-12-12 | The Macfarlane Burnet Institute For Medical Research And Public Health Ltd | A method of treatment and compositions useful therefor, screening and prognostic agents and uses therefor |
EP2858637A1 (en) | 2012-06-12 | 2015-04-15 | F. Hoffmann-La Roche AG | Combination of therapeutic agents for treating hcv infection |
MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
CA2819967C (en) | 2012-08-31 | 2016-03-22 | Intermune, Inc. | Use of pirfenidone concomitantly with ciprofloxacin |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
US9156896B2 (en) | 2013-03-15 | 2015-10-13 | Coda Therapeutics, Inc. | Wound healing compositions and treatments |
CN105188758A (zh) | 2013-03-15 | 2015-12-23 | 梅迪奇斯医药公司 | 氟尼缩松的局部组合物及治疗方法 |
MX352342B (es) | 2013-07-12 | 2017-11-22 | Moleculas Naturales S A De C V Star | Un procedimiento para fabricar un complejo mejorado de cloruro de bencetonio-dialil oxido de disulfuro modificado, el complejo obtenido y sus usos. |
CN103550242B (zh) | 2013-11-22 | 2015-07-15 | 四川国康药业有限公司 | 一种治疗肝纤维化的药物组合物及其制备方法 |
GB201508419D0 (en) | 2015-05-15 | 2015-07-01 | Cambridge Entpr Ltd | Detection of T cell exhaustion or lack of T cell costimulation and uses thereof |
KR20180093932A (ko) | 2015-12-16 | 2018-08-22 | 다이이찌 산쿄 가부시키가이샤 | 창상 치료제 |
JOP20170113B1 (ar) | 2016-05-09 | 2023-03-28 | Bayer Pharma AG | مركبات 5، 6، 7، 8-رباعي هيدرو [1، 2، 4] تريازولو [4، 3-أ] بيريدين 3(2h)-ون مستبدلة ومركبات 2، 5، 6، 7-رباعي هيدرو-3h-بيرولو [2، 1-ج] [1، 2، 4] تريازول-3-ون واستخداماتها |
MX364040B (es) | 2016-11-11 | 2019-04-11 | Cell Therapy And Tech S A De C V | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash). |
TWI770157B (zh) | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途 |
MX366086B (es) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel. |
MX368750B (es) | 2018-08-31 | 2019-10-15 | Cell Therapy And Tech S A De C V | Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular. |
-
2012
- 2012-03-28 MX MX2012003694A patent/MX346763B/es active IP Right Grant
-
2013
- 2013-02-27 JP JP2015503144A patent/JP2015513359A/ja active Pending
- 2013-02-27 MA MA37377A patent/MA20150062A1/fr unknown
- 2013-02-27 CA CA2868729A patent/CA2868729C/en active Active
- 2013-02-27 WO PCT/MX2013/000027 patent/WO2013147577A1/es active Application Filing
- 2013-02-27 US US14/388,447 patent/US20150148382A1/en not_active Abandoned
- 2013-02-27 CN CN201380023489.8A patent/CN104334171A/zh active Pending
- 2013-02-27 EP EP13716457.0A patent/EP2832354A1/en not_active Withdrawn
- 2013-02-27 KR KR1020147030122A patent/KR20140146144A/ko not_active Application Discontinuation
- 2013-02-27 EA EA201401031A patent/EA201401031A1/ru unknown
- 2013-02-27 IN IN8067DEN2014 patent/IN2014DN08067A/en unknown
- 2013-02-27 SG SG11201406035VA patent/SG11201406035VA/en unknown
- 2013-02-27 AU AU2013240709A patent/AU2013240709A1/en not_active Abandoned
- 2013-03-20 UY UY0001034700A patent/UY34700A/es unknown
- 2013-03-21 AR ARP130100926A patent/AR090457A1/es unknown
-
2014
- 2014-09-22 TN TNP2014000396A patent/TN2014000396A1/fr unknown
- 2014-09-23 IL IL234816A patent/IL234816A0/en unknown
- 2014-09-24 CO CO14211037A patent/CO7071140A2/es unknown
- 2014-09-26 CU CU2014000114A patent/CU20140114A7/es unknown
- 2014-09-26 PH PH12014502154A patent/PH12014502154A1/en unknown
- 2014-09-26 CL CL2014002591A patent/CL2014002591A1/es unknown
- 2014-09-26 DO DO2014000218A patent/DOP2014000218A/es unknown
-
2016
- 2016-04-14 US US15/098,970 patent/US9949959B2/en active Active
-
2018
- 2018-03-14 US US15/920,822 patent/US20180214434A1/en not_active Abandoned
-
2019
- 2019-08-07 US US16/534,980 patent/US11013727B2/en active Active
-
2021
- 2021-05-24 US US17/328,685 patent/US11766426B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4987677A (es) | 1972-12-18 | 1974-08-22 | ||
US3839346A (en) | 1972-12-18 | 1974-10-01 | Affiliated Med Res | N-substituted pyridone and general method for preparing pyridones |
US3974281A (en) | 1972-12-18 | 1976-08-10 | Affiliated Medical Research, Inc. | 5-Methyl-1-phenyl-2-(1H)-pyridone compositions and methods of use |
US4042699A (en) | 1972-12-18 | 1977-08-16 | Affiliated Medical Research, Inc. | Method for reducing serum glucose levels |
US4052509A (en) | 1972-12-18 | 1977-10-04 | Affiliated Medical Research, Inc. | Method for reducing serum uric acid levels |
JPS51128433A (en) | 1975-04-30 | 1976-11-09 | Ajinomoto Co Inc | A herbicide |
EP2177220A1 (en) * | 2007-08-14 | 2010-04-21 | Cell Therapy Technology, S.A. DE C.V. | Gel containing pirfenidone |
Non-Patent Citations (3)
Title |
---|
ANONYMOUS: "Acne treatment", 21 July 2010 (2010-07-21), XP002696538, Retrieved from the Internet <URL:http://www.allicinnow.com/allicin/acne-treatment/> [retrieved on 20130502] * |
ARMENDARIZ-BORUNDA JUAN ET AL: "A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients", ANNALS OF PLASTIC SURGERY, vol. 68, no. 1, 1 January 2012 (2012-01-01), LITTLE, BROWN AND CO, US, pages 22 - 28, XP009169363, ISSN: 0148-7043, DOI: 10.1097/SAP.0B013E31821B6D08 * |
PETER JOSLING: "Peter Josling's PowerPoint on AllicinCenter Products and their uses", 2009, XP002696537, Retrieved from the Internet <URL:http://allicincenter.com/reference.php?id=products> [retrieved on 20130502] * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11779574B2 (en) | 2007-08-14 | 2023-10-10 | Excalibur Pharmaceuticals, Inc. | Gel containing pirfenidone |
US10376500B2 (en) | 2007-08-14 | 2019-08-13 | Cell Therapy and Technology S.A. DE C.V. | Gel containing pirfenidone |
US11083719B2 (en) | 2007-08-14 | 2021-08-10 | Excalibur Pharmaceuticals, Inc. | Gel containing Pirfenidone |
US11040030B2 (en) | 2011-07-19 | 2021-06-22 | Excalibur Pharmaceuticals, Inc. | Methods of using a pharmaceutical composition containing pirfenidone in sustained-release tablet form |
US11052074B2 (en) | 2011-07-19 | 2021-07-06 | Excalibur Pharmaceuticals, Inc. | Process for the preparation of a pharmaceutical composition containing pirfenidone in sustained-release tablet form and its application in the regression of human chronic renal failure, breast capsular contracture and hepatic fibrosis |
US11013727B2 (en) | 2012-03-28 | 2021-05-25 | Excalibur Pharmaceuticals, Inc. | Semi-solid topical composition containing pirfenidone and modified diallyl disulfide oxide (M-DDO) for eliminating or preventing acne |
US9949959B2 (en) | 2012-03-28 | 2018-04-24 | Cell Therapy and Technology S.A. DE C.V. | Semi-solid topical composition containing pirfenidone and modified diallyl disulfide oxide (M-DDO) for eliminating or preventing acne |
US11766426B2 (en) | 2012-03-28 | 2023-09-26 | Excalibur Pharmaceuticals, Inc. | Semi-solid topical composition containing pirfenidone and modified diallyl disulfide oxide (M-DDO) for eliminating or preventing acne |
US10792258B2 (en) | 2012-08-23 | 2020-10-06 | Excalibur Pharmaceuticals, Inc. | Antiseptic, antiseborrheic and exfoliating composition to remove or prevent acne |
US10544161B2 (en) | 2014-04-02 | 2020-01-28 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10233195B2 (en) | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
US11576905B2 (en) | 2017-08-15 | 2023-02-14 | Excalibur Pharmaceuticals, Inc. | Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage |
WO2020046102A3 (es) * | 2018-08-31 | 2020-09-10 | Cell Therapy and Technology S.A. DE C.V. | Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular |
Also Published As
Publication number | Publication date |
---|---|
MX2012003694A (es) | 2013-09-30 |
CO7071140A2 (es) | 2014-09-30 |
US11766426B2 (en) | 2023-09-26 |
IN2014DN08067A (es) | 2015-05-01 |
US20210346360A1 (en) | 2021-11-11 |
MA20150062A1 (fr) | 2015-02-27 |
AR090457A1 (es) | 2014-11-12 |
IL234816A0 (en) | 2014-12-31 |
UY34700A (es) | 2013-10-31 |
TN2014000396A1 (en) | 2015-12-21 |
US20180214434A1 (en) | 2018-08-02 |
CN104334171A (zh) | 2015-02-04 |
US20150148382A1 (en) | 2015-05-28 |
AU2013240709A1 (en) | 2014-11-06 |
KR20140146144A (ko) | 2014-12-24 |
CL2014002591A1 (es) | 2015-01-16 |
EP2832354A1 (en) | 2015-02-04 |
US20200061040A1 (en) | 2020-02-27 |
JP2015513359A (ja) | 2015-05-11 |
SG11201406035VA (en) | 2014-11-27 |
CA2868729C (en) | 2020-10-20 |
PH12014502154A1 (en) | 2014-12-10 |
DOP2014000218A (es) | 2014-12-15 |
CA2868729A1 (en) | 2013-10-03 |
CU20140114A7 (es) | 2015-01-29 |
US9949959B2 (en) | 2018-04-24 |
MX346763B (es) | 2017-03-31 |
EA201401031A1 (ru) | 2015-05-29 |
US20160228424A1 (en) | 2016-08-11 |
US11013727B2 (en) | 2021-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013147577A1 (es) | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné | |
Borda et al. | Treatment of seborrheic dermatitis: a comprehensive review | |
US20190216886A1 (en) | Topical Compositions And Methods For Treating Wounds | |
US20130123221A1 (en) | Compositions and methods for the treatment of skin diseases | |
US20160213690A1 (en) | Compositions and methods for the treatment of skin diseases | |
WO2014030992A2 (es) | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné | |
CN107519236A (zh) | 一种治疗灰指甲的外用药剂 | |
US20210244785A1 (en) | Compositions and methods for the antiseptic treatment of biofilms on mammalian tissue | |
JP2021503002A (ja) | 皮膚および粘膜感染症の局所治療用エマルション | |
CN102526056B (zh) | 一种伏立康唑滴耳液及其制备方法和用途 | |
DE602004011786T2 (de) | Taurin bromamin für die inhibierung von pathogenen bakterien und pilzwachstum sowie in einer mikrobiziden zusammensetzung | |
US20240216350A1 (en) | Semi-solid topical composition containing pirfenidone and modified diallyl disulfide oxide (m-ddo) for eliminating or preventing acne | |
US20110305747A1 (en) | Combination of dapsone with other anti-acne agents | |
US20170119703A1 (en) | Methods of treatment of acne vulgaris using topical dapsone compositions | |
CN113413331A (zh) | 祛痘组合物及其制剂和用途 | |
Powell et al. | The Future of Rosacea Treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13716457 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2014-000434 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14211037 Country of ref document: CO Ref document number: 001472-2014 Country of ref document: PE |
|
ENP | Entry into the national phase |
Ref document number: 2868729 Country of ref document: CA Ref document number: 2015503144 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014002591 Country of ref document: CL Ref document number: IDP00201405804 Country of ref document: ID |
|
WWE | Wipo information: entry into national phase |
Ref document number: P1036/2014 Country of ref document: AE |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201401031 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014023836 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013716457 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20147030122 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2013240709 Country of ref document: AU Date of ref document: 20130227 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14388447 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 112014023836 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140925 |